All News

guidelines.recommendations.jpg

BSR Guideline for Psoriatic Arthritis - 2022 Update

d Jack Cush, MD

The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy. 

Read Article
Malar,rash,SLE, Lupus

Emerging Therapeutics for Lupus

d Kathryn H. Dao, M.D.

Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast. 

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

d Jack Cush, MD

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article
Axial Spondyloarthritis

Update on Axial SpA at EULAR 2022

d Antoni Chan, MD, PhD

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

d Eric Dein, MD

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.

Read Article
VIDEO: Golden Window in Pre-RA Dr. Richard Conway ( @RichardPAConway) discusses abstract OP0070 presented at #EULAR2022. https://t.co/VoVo4TTgvO https://t.co/7NrZqJlwjo

Links:

Dr. John Cush RheumNow ( View Tweet)
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/AVQ7lRYoRw

Links:

Dr. John Cush RheumNow ( View Tweet)

PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals? POS0309 at #EULAR2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies. https://t.co/8newrxP1hn https://t.co/c9SwrRd8mw

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: Severe Hematologic Relapse Risk in SLE Dr. Kathryn Dao ( @KDAO2011) discusses POS0365 presented at the #EULAR2022 meeting. https://t.co/a0LgsEZ0w4 https://t.co/Ajl22OIHxD

Links:

Dr. John Cush RheumNow ( View Tweet)
Topical therapies take centre stage Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022 https://t.co/V9plk1vAEd https://t.co/fyNWWtconi

Links:

Dr. John Cush RheumNow ( View Tweet)
🆒 Couldn't attend my #EULAR2022 talk about the role of #twitter in #Rheumatology? Check the 2 slides below summarizing the role of #socialmedia for the dissemination of medical information. #TwitterRheum ⬇️ BEFORE vs AFTER Twitter ⬇️ https://t.co/ZzVdoWYEMr
Laurent ARNAUD Lupusreference ( View Tweet)
Updates on Axial SpA from #EULAR2022 @RheumNow https://t.co/0dGPUpksxT

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

EULAR recommendations for management of #RheumatoidArthritis 6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible 8️⃣JAKi can be used but consider risk factors via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
#good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a receptor blocker - maintains more remission and less relapses and less total prednisone OP0180 @eular_org #EULAR2022 @RheumNow Bad news $$💰 will limit access.

Janet Pope Janetbirdope ( View Tweet)

#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Janet Pope Janetbirdope ( View Tweet)
Watch: #EULAR2022 - Day 4 Faculty Panel Recap Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006. https://t.co/B7AYkTnAe0 https://t.co/NF3f6AFv6K

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on Axial SpA at #EULAR2022 This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). Dr Antoni Chan shares his picks of abstracts from the conference. https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 – Day 4 Report Check out our my favorite late-breakers from Day 4. https://t.co/R0hPetOos4 https://t.co/T57XRIKZs5

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: Not Your Kind of RA Dr. David Liew discusses abstract OP0035 presented at #EULAR2022 Background: It has been suggested that rheumatoid arthritis (RA) starts at a younger age in cities with a lower latitude (closer to both sides of the equator). https://t.co/0l8b95emkn https://t.co/2leBR1nOBJ

Links:

Dr. John Cush RheumNow ( View Tweet)
×